CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients
Choong-kun Lee, Hong Jae Chon, Woo Sun Kwon, Hyo-Jeong Ban, Sang Cheol Kim, Hyunwook Kim, Hei-Cheul Jeung, Jimyung Chung, Sun Young Rha
Genomics Inform. 2022;20(3):e29  Published online September 30, 2022
DOI: https://doi.org/10.5808/gi.22051

Excel Download

The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients
Choong-kun Lee, Hong Jae Chon, Woo Sun Kwon, Hyo-Jeong Ban, Sang Cheol Kim, Hyunwook Kim, Hei-Cheul Jeung, Jimyung Chung, Sun Young Rha
Genomics & Informatics. 2022;20(3):e29   Crossref logo
Link1 Link2 Link3
Pricing transparency among several needs for patients with high‐risk breast cancer
Ashley Hay
Cancer. 2021;127(22):4122-4123   Crossref logo
Link1 Link2 Link3
Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population
BMJ. 2015;h4134   Crossref logo
Link1 Link2
Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial
Michael Gubanski, , Anders Johnsson, Eva Fernebro, Lianna Kadar, Ingegerd Karlberg, Petra Flygare, Åke Berglund, Bengt Glimelius, Pehr A. Lind
Gastric Cancer. 2010;13(3):155-161   Crossref logo
Link1 Link2 Link3
Concurrent radiation with irinotecan and carboplatin in intermediate- and high-risk rhabdomyosarcoma: A report on toxicity and efficacy from a prospective pilot phase II study
Kavita V. Dharmarajan, Leonard H. Wexler, Suzanne L. Wolden
Pediatric Blood & Cancer. 2012;60(2):242-247   Crossref logo
Link1 Link2 Link3
Predicting the Bleeding Risk for Patients on Anticoagulant Therapy Prior to Gastric Endoscopic Submucosal Dissection
Jie-Hyun Kim
Journal of Gastric Cancer. 2022;22(1):1   Crossref logo
Link1 Link2 Link3
Combination chemotherapy with irinotecan and cisplatin in pretreated patients with unresectable or recurrent gastric cancer
Shinya Ueda, Shuichi Hironaka, Narikazu Boku, Akira Fukutomi, Takayuki Yoshino, Yusuke Onozawa
Gastric Cancer. 2006;9(3):203-207   Crossref logo
Link1 Link2 Link3
A phase II study of biweekly mitomycin C and irinotecan combination therapy in patients with fluoropyrimidine-resistant advanced gastric cancer: a report from the Gastrointestinal Oncology Group of the Japan Clinical Oncology Group (JCOG0109-DI Trial)
Tetsuya Hamaguchi, , Kuniaki Shirao, Atsushi Ohtsu, Ichinosuke Hyodo, Yasuaki Arai, Hiroya Takiuchi, Hirofumi Fujii, Motoki Yoshida, Hiroshi Saito, Tadamichi Denda, Wasaburo Koizumi, Hiroaki Iwase, Narikazu Boku
Gastric Cancer. 2011;14(3):226-233   Crossref logo
Link1 Link2 Link3 Link4
Associations between UGT1A1*6/*28 polymorphisms and irinotecan-induced severe toxicity in Chinese gastric or esophageal cancer patients
Jing Gao, Jun Zhou, Yanyan Li, Zhi Peng, Yilin Li, Xicheng Wang, Lin Shen
Medical Oncology. 2013;30(3):   Crossref logo
Link1 Link2 Link3
UGT1A1*28 genotype and irinotecan dosage in patients with metastatic colorectal cancer: a Dutch Colorectal Cancer Group study
D M Kweekel, H Gelderblom, T Van der Straaten, N F Antonini, C J A Punt, H-J Guchelaar
British Journal of Cancer. 2008;99(2):275-282   Crossref logo
Link1 Link2 Link3